Background
Methods
Subjects and data collection
Definition of DM and determination of glycemic variability
Statistical analysis
Results
Demographic and GV-related data
All | Low GV | High CV | p value | |
---|---|---|---|---|
(MAGE ≦ 65) | (MAGE > 65) | |||
(N = 452) | (N = 256) | (N = 196) | ||
Basic and glycemia data | ||||
Age (years) | 71.4 ± 14.7 | 71.7 ± 15.3 | 71.2 ± 13.9 | 0.72 |
Male % | 346 (76.7%) | 206 (80.8%) | 140 (71.4%) | 0.03 |
BMI (kg) | 23.7 ± 8.8 | 24 ± 11 | 23.3 ± 4.5 | 0.36 |
HbA1c (%) | 6.3 ± 1.4 | 5.9 ± 0.9 | 6.7 ± 1.8 | < 0.01 |
Day 1 glucose metrics | ||||
Mean glucose (mg/dL) | 164.1 ± 41.7 | 148.7 ± 31.0 | 184.2 ± 45.1 | < 0.01 |
Peak glucose (mg/Dl) | 239.9 ± 81.6 | 194.7 ± 50.3 | 298.9 ± 76.9 | < 0.01 |
Hypoglycemia (< 40 mg/dL) | 2 (0.4%) | 0 (0%) | 2 (1.0%) | 0.18 |
Glycemic variation | ||||
MAGE | 67 ± 51.1 | 33.7 ± 18.6 | 110.5 ± 47.2 | < 0.01 |
CoV | 23.5 ± 11.2 | 17.2 ± 7.1 | 31.8 ± 10.1 | < 0.01 |
Comorbidities | ||||
Diabetes mellitus | 158 (35%) | 60 (23.4%) | 98 (50.0%) | < 0.01 |
Congestive heart failure | 143 (31.6%) | 74 (28.9%) | 69 (35.2%) | 0.19 |
Cerebrovascular disease | 50 (11.1%) | 27 (10.5%) | 23 (11.7%) | 0.80 |
Chronic airway disease | 127 (28.1%) | 70 (27.3%) | 57 (29.1%) | 0.76 |
Chronic renal disease | 53 (11.7%) | 26 (10.2%) | 27 (13.8%) | 0.30 |
Malignancy | 108 (23.9%) | 64 (25.0%) | 44 22.4(%) | 0.60 |
Severity-associated variables | ||||
APACHE II score | 27.4 ± 6.6 | 27.3 ± 6.6 | 27.5 ± 6.6 | 0.70 |
Lactate level, 0 h (mg/dl) | 26.5 ± 23.6 | 24.5 ± 20.1 | 29.1 ± 27.4 | 0.05 |
Lactate level, 24 h (mg/dl) | 21.7 ± 19.6 | 19.9 ± 15.9 | 24.2 ± 23.6 | 0.10 |
ScvO2, 0 h (%) | 74.7 ± 11.4 | 74.4 ± 11.3 | 75.2 ± 11.7 | 0.45 |
ScvO2, 6 h (%) | 74.6 ± 10.5 | 74.8 ± 10.5 | 74.3 ± 10.4 | 0.61 |
Laboratory data | ||||
Albumin (mg/dL) | 2.8 ± 0.6 | 2.9 ± 0.6 | 2.8 ± 0.6 | 0.21 |
Hemoglobin (g/dL) | 10.2 ± 2.3 | 10.3 ± 2.3 | 10.1 ± 2.4 | 0.29 |
Creatinine (mg/dL) | 2.1 ± 2.2 | 1.9 ± 1.8 | 2.3 ± 2.6 | 0.07 |
C-reactive protein (mg/dL) | 13.8 ± 10.6 | 14 ± 10.2 | 13.7 ± 11.1 | 0.80 |
Procalcitonin (ng/mL) | 17.4 ± 34.9 | 17 ± 34.5 | 17.8 ± 35.5 | 0.82 |
Outcomes | ||||
30-day mortality | 140 (31%) | 68 (26.6%) | 72 (36.7%) | 0.03 |
High day 1 GV was associated with high 30-day mortality
Characteristics | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age, per 1 year increment | 1.003 (0.991–1.014) | 0.63 | 1.005 (0.993–1.018) | 0.41 |
Sex | ||||
Female | 1 [Reference] | 1 [Reference] | ||
Male | 1.113 (0.743–1.667) | 0.60 | 1.292 (0.822–2.031) | 0.27 |
HbA1c, per 1 increment | 1.045 (0.935–1.167) | 0.44 | 0.919 (0.803–1.051) | 0.92 |
Cerebrovascular disease | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 0.602 (0.317–1.146) | 0.12 | 0.502 (0.255–0.986) | 0.05 |
Chronic pulmonary disease | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 0.506 (0.328–0.779) | < 0.01 | 0.483 (0.305–0.764) | < 0.01 |
APACHE II, per 1 increment | 1.056 (1.027–1.086) | < 0.01 | 1.045 (1.013–1.078) | < 0.01 |
Lactate 0-h, per 1 mg/dL increment | 1.010 (1.005–1.014) | < 0.01 | 1.009 (1.003–1.014) | < 0.01 |
Hemoglobin, per 1 g/dL increment | 0.967 (0.818–2.672) | 0.40 | 1.002 (09.25–1.085) | 0.97 |
Creatinine, per 1 mg/dL increment | 1.048 (0.993–1.105) | 0.09 | 1.031 (0.954–1.115) | 0.44 |
Hypoglycemia episode (< 40 mg/dL) | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 2.098 (0.293–15.009) | 0.46 | 1.947 (0.245–15.47) | 0.53 |
Mean day 1 glucose, per 1 mg/dL increment | 1.004 (1.000–1.008) | 0.04 | 1.008 (1.000–1.016) | 0.04 |
Peak day 1 glucose, per 1 mg/dL increment | 1.002 (1.000–1.004) | 0.08 | 0.997 (0.992–1.001) | 0.18 |
MAGE, cut-off point 65 mg/dL | ||||
Low | 1 [Reference] | 1 [Reference] | ||
High | 1.488 (1.068–2.072) | 0.02 | 1.607 (1.008–2.563) | 0.04 |
Using CoV to assess GV
Characteristics | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age, per 1 year increment | 1.003 (0.991–1.014) | 0.63 | 1.006 (0.993–1.019) | 0.38 |
Sex | ||||
Female | 1 [Reference] | 1 [Reference] | ||
Male | 1.113 (0.743–1.667) | 0.60 | 1.251 (0.798–1.959) | 0.33 |
HbA1c, per 1 increment | 1.045 (0.935–1.167) | 0.44 | 0.926 (0.804–1.066) | 0.28 |
Cerebrovascular disease | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 0.602 (0.317–1.146) | 0.12 | 0.432 (0.218–0.856) | 0.01 |
Chronic pulmonary disease | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 0.506 (0.328–0.779) | < 0.01 | 0.506 (0.320–0.800) | < 0.01 |
APACHE II, per 1 increment | 1.056 (1.027–1.086) | < 0.01 | 1.040 (1.008–1.073) | < 0.01 |
Lactate 0-h, per 1 mg/dL increment | 1.010 (1.005–1.014) | < 0.01 | 1.009 (1.003–1.015) | < 0.01 |
Hemoglobin, per 1 g/dL increment | 0.967 (0.818–2.672) | 0.40 | 0.983 (0.906–1.066) | 0.68 |
Creatinine, per 1 mg/dL increment | 1.048 (0.993–1.105) | 0.09 | 1.028 (0.949–1.113) | 0.50 |
Hypoglycemia episode (< 40 mg/dL) | ||||
No | 1 [Reference] | 1 [Reference] | ||
Yes | 2.098 (0.293–15.009) | 0.46 | 1.660 (0.209–13.203) | 0.63 |
Mean day 1 glucose, per 1 mg/dL increment | 1.004 (1.000–1.008) | 0.04 | 1.014 (1.005–1.024) | < 0.01 |
Peak day 1 glucose, per 1 mg/dL increment | 1.002 (1.000–1.004) | 0.08 | 0.993 (0.987–0.998) | 0.01 |
CoV, cut-off point 30% | ||||
Low | 1 [Reference] | 1 [Reference] | ||
High | 1.683 (1.191–2.378) | < 0.01 | 2.593 (1.494–4.499) | < 0.01 |